Yoseph Shaaltiel, Executive VP, R&D at Protalix BioTherapeutics, Inc. (PLX), sold 1,309 shares at $7.00 ($9K) on 2010-04-14, disclosed to the SEC on 2010-04-16.
Scheduled sale ($9k) by Executive VP, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| PLX | SELL | 2010-06-23 | $371K | — | Filing → |
| PLX | SELL | 2010-05-03 | $89K | — | Filing → |
| PLX | SELL | 2010-03-25 | $2.7M | — | Filing → |